Monthly Archives: July 2022

PSNC has agreed to take forward a comprehensive new programme of work to address the 21 RSG proposals that were directed at the Committee. Alongside that, the Committee has reaffirmed its commitment to supporting LPCs through the proposed changes for them, and to working together with LPCs on the 10 joint PSNC and LPC proposals. [...]

The post PSNC launches Transforming Pharmacy Representation (TAPR) Programme    appeared first on PSNC Website.

A new Medicines and Healthcare products Regulatory Agency (MHRA) Drug Safety Update (Vol 15 Issue 12 July 2022) has been published and includes articles on: Topiramate (Topamax): start of safety review triggered by a study reporting an increased risk of neurodevelopmental disabilities in children with prenatal exposure COVID-19 vaccines and medicines: updates for July 2022 [...]

The post MHRA Drug Safety Update July 2022 appeared first on PSNC Website.

Class 4 Medicines Defect Information: NovoRapid® FlexTouch® 100 units/ml and Saxenda® FlexTouch® (liraglutide) 6mg/ml (Novo Nordisk Limited) Drug alert number: EL (22)A/33 Date issued: 21 July 2022 The Medicines and Health products Regulatory Agency (MHRA) has issued a class 4 medicines defect information notice for: Novorapid FlexTouch 100units/ml solution for injection in pre-filled pen (insulin [...]

The post MHRA Class 4 Medicines Defect Information: NovoRapid FlexTouch 100units/ml and Saxenda FlexTouch 6mg/ml appeared first on PSNC Website.

PSNC is becoming increasingly concerned about the sustained pressures on medicines supply and the very serious impact that this is having on community pharmacy teams and their patients. As we move into the second half of the year, we are asking contractors and their teams to continue using our regular reporting tools to help us [...]

The post Medicine supply: Contractor Update from PSNC   appeared first on PSNC Website.